Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioCryst downplays embarrassing error

A red-faced BioCryst Pharmaceuticals Inc. announced that an incorrect randomization key is responsible for Phase II data that were erroneously reported in February to be statistically significant.

"Obviously, it's very embarrassing for the company," BCRX Director of Corporate Development John Higgins told BioCentury. However, he said, the development timeline for the

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers